IL17A and systemic lupus erythematosus: It was observed that, in LAD-I patients, the identified CD3+CD8−CD56−TCRgd−IL-17 producers were presumed to be CD4+ [T helper 17 (TH17)]; however, the authors cannot rule out that these cells might in fact be a population of CD3+CD4−CD8− cells similar to the ones identified in patients with systemic lupus erythematosus or Sjögren’s syndrome as dominant sources of pathogenic IL-17 [23,24].